Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to demonstrate the efficacy and safety of quetiapine fumarate (SEROQUEL) in the treatment of adolescent patients with schizophrenia and bipolar I disorder.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Quetiapine Fumarate

Criteria

Inclusion Criteria:

• Patient is able to provide written assent and the parents or legal guardian of the patient are/is able to provide written informed consent before beginning any study related procedures

• Patient previously enrolled in either double-blind Study D1441C00149 or D1441C00112

• Patient has documented clinical diagnosis of schizophrenia or bipolar I disorder

• Patient's parent or legal guardian will be able to accompany the patient to each scheduled study visit

Exclusion Criteria:

• Patients (female) must not be pregnant or lactating

• Patients with a known intolerance or lack of response to previous treatment with quetiapine

• Patients who have previously participated in this study